Open

Combo Chemo, Bev &/or Atezo in Treating Patients w/Deficient DNA Mismatch Repair Metastatic CRC

To determine if treatment with mFOLFOX6/bevacizumab plus atezolizumab ) and atezolizumab is more effective than treatment with mFOLFOX6/bevacizumab alone in patients with metastatic colon cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

United States (Nationwide)

What will be asked of you

In screening, patients will receive an MD visit, blood tests, urinalysis, imaging scan, electrocardiogram (EKG), and questionnaires. During treatment, patients will receive MD visits, blood tests, urinalysis, imaging scans, study drug treatment, and questionnaires.

In-person visits:
20-50 (depends on how quickly they progress on treatment).

Total length of participation:
Up to five years.

Looking for Specific Volunteers

Able to participate:

Participant must have colon or rectum cancer that has spread (metastatic).
Participant must not have had any previoud treatment of their colorectal cancer that spread (metastatic).
Participant must have genetic testing that shows the tumor to be mismatch-repair deficient (dMMR).

Not eligible if:

Participant has any cancer that spread to the brain (some exceptions apply).
Participant has uncontrolled high blood pressure defined as systolic blood pressure (BP)>150mmHg with or without anti-hypertensive medication.
Participant has a history of transient ischemic attack (TIA), cerebrovascular accident (CVA), gastrointestinal (GI) perforation or arterial thrombotic event within 6 months prior to randomization.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Trials Office
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Hanna Sanoff
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Colorectal)

IRB Number

18-1438

ClinicalTrials.gov

NCT02997228

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.